Trial Profile
Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 10 Dec 2019 Results of a pooled analysis assessing patterns of renal recovery and toxicity by using data from two studies including this study presented at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 01 Nov 2017 Results published in the British Journal of Haematology
- 17 Apr 2013 Planned number of patients changed from 400 to 401 as reported by German Clinical Trials Register.